연구동향 분석
박사

알츠하이머병 동물모델에서 산조인의 인지능 개선 효과에 관한 연구 = Studies on the attenuating effects of the Ziziphus jujuba var. spinosa against cognitive deficit in Alzheimer’s disease mouse model

정인호 2019년

논문상세정보
인용/피인용
' 알츠하이머병 동물모델에서 산조인의 인지능 개선 효과에 관한 연구 = Studies on the attenuating effects of the Ziziphus jujuba var. spinosa against cognitive deficit in Alzheimer’s disease mouse model' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • 5XFAD mouse
  • Amyloid β
  • Brain derived neurotrophic factor
  • Long-term potentiation
  • alzheimer’s disease
  • plasmin
  • ziziphus jujuba var. spinosa
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
289 0

0.0%

' 알츠하이머병 동물모델에서 산조인의 인지능 개선 효과에 관한 연구 = Studies on the attenuating effects of the Ziziphus jujuba var. spinosa against cognitive deficit in Alzheimer’s disease mouse model' 의 참고문헌

  • Zhang, L., Y. Fang, Y. Xu, Y. Lian, N. Xie, T. Wu, H. Zhang, L. Sun, R. Zhang, and Z. Wang. 2015. Curcumin improves amyloid beta-Peptide1-42 induced spatial memory deficits through BDNF-ERK Signaling Pathway. PLOS One. 10:e0131525.
  • You, Z.L., Q. Xia, F.R. Liang, Y.J. Tang, C.L. Xu, J. Huang, L. Zhao, W.Z. Zhang, and J.J. He. 2010. Effects on the expression of GABAA receptor subunits by jujuboside A treatment in rat hippocampal neurons. Journal of Ethnopharmacology. 128:419-423.
  • Yepes, M. 2015. Tissue-type plasminogen activator is a neuroprotectant in the central nervous system. Frontiers Cellular Neuroscience. 9:304.
  • Yang, B., H. Yang, F. Chen, Y. Hua, and Y. Jiang. 2013. Phytochemical analyses of Ziziphus jujuba Mill. var. spinosa seed by ultrahigh performance liquid chromatography-tandem mass spectrometry and gas chromatography-mass spectrometry. Analyst. 138:6881-6888.
  • Yamada, K. and T. Nabeshima. 2003. Brain-derived neurotrophic factor/TrkB Signaling in memory processes. Journal of Pharmacological Sciences. 91:267-270.
  • Wu, C.C., C.C. Lien, W.H. Hou, P.M. Chiang, and K.J. Tsai. 2016. Gain of BDNF function in engrafted neural stem cells promotes the therapeutic potential for Alzheimer's disease. Scientific Reports. 6:27358.
  • Winblad, B., G. Grossberg, L. Frolich, M. Farlow, S. Zechner, J. Nagel, and R. Lane. 2007. IDEAL: A 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease. Neurology. 69:S14-22.
  • Weller, R.O., M. Subash, S.D. Preston, I. Mazanti, and R.O. Carare. 2008. Perivascular drainage of amyloid-beta peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer's disease. Brain Pathology. 18:253-266.
  • Watari, H., Y. Shimada, and C. Tohda. 2014. New treatment for Alzheimer's disease, kamikihito, reverses amyloid-beta-induced progression of Tau phosphorylation and axonal atrophy. Evidence-based Complementary and Alternative Medicine. 2014:706487.
  • Watari, H., M. Shigyo, N. Tanabe, M. Tohda, K.H. Cho, P.S. Kyung, W.S. Jung, Y. Shimada, N. Shibahara, T. Kuboyama, and C. Tohda. 2015. Comparing the effects of kamikihito in Japan and kami-guibi-tang in Korea on memory enhancement: Working towards the development of a global study. Phytotherapy Research. 29:351-356.
  • Wang, X.X., G.I. Ma, J.B. Xie, and G.C. Pang. 2015. Influence of JuA in evoking communication changes between the small intestines and brain tissues of rats and the GABAA and GABAB receptor transcription levels of hippocampal neurons. Journal of Ethnopharmacology. 159:215-223.
  • Wang, X., B. Yang, A. Zhang, H. Sun, and G. Yan. 2012. Potential drug targets on insomnia and intervention effects of jujuboside A through metabolic pathway analysis as revealed by UPLC/ESI-SYNAPT-HDMS coupled with pattern recognition approach. Journal of Proteomics. 75:1411-1427.
  • Wagner, U., M. Utton, J.M. Gallo, and C.C. Miller. 1996. Cellular phosphorylation of tau by GSK-3 beta influences tau binding to microtubules and microtubule organisation. Journal of Cell Science. 109:1537-1543.
  • Vassar, R. 2014. BACE1 inhibitor drugs in clinical trials for Alzheimer's disease. Alzheimer's Research and Therapy. 6:89.
  • Van Marum, R.J. 2009. Update on the use of memantine in Alzheimer’s disease. Neuropsychiatric Disease and Treatment. 5:237.
  • Tucker, H.M., M. Kihiko, J.N. Caldwell, S. Wright, T. Kawarabayashi, D. Price, D. Walker, S. Scheff, J.P. McGillis, R.E. Rydel, and S. Estus. 2000. The plasmin system is induced by and degrades amyloid-β aggregates. Journal of Neuroscience. 20:3937-3946.
  • Trojanowski, J.Q. and V.M. Lee. 2005. Pathological tau: A loss of normal function or a gain in toxicity? Nature Neuroscience. 8:1136-1137.
  • Touchon, J., H. Bergman, R. Bullock, G. Rapatz, J. Nagel, and R. Lane. 2006. Response to rivastigmine or donepezil in Alzheimer's patients with symptoms suggestive of concomitant Lewy body pathology. Current Medical Research and Opinion. 22:49-59.
  • Tohda, C., R. Naito, and E. Joyashiki. 2008. Kihi-to, a herbal traditional medicine, improves Abeta(25-35)-induced memory impairment and losses of neurites and synapses. BMC Complementary and Alternative Medicine. 8:49.
  • Siegel, G.J. and N.B. Chauhan. 2000. Neurotrophic factors in Alzheimer's and Parkinson's disease brain. Brain Research Reviews. 33:199-227.
  • Shergis, J.L., X. Ni, J. Sarris, A.L. Zhang, X. Guo, C.C. Xue, C. Lu, and H. Hugel. 2017. Ziziphus spinosa seeds for insomnia: A review of chemistry and psychopharmacology. Phytomedicine. 34:38-43.
  • Selkoe, D.J. and D. Schenk. 2003. Alzheimer's disease: Molecular understanding predicts amyloid-based therapeutics. Annual Review of Parmacology and Toxicology. 43:545-584.
  • Seeman, P., C. Caruso, and M. Lasaga. 2008. Memantine agonist action at dopamine D2High receptors. Synapse. 62:149-153.
  • Samadi, H., and D. Sultzer. 2011. Solanezumab for Alzheimer's disease. Expert Opinion Biological Therapy. 11:787-798.
  • Saido, T. and M.A. Leissring. 2012. Proteolytic degradation of amyloid β-protein. Cold Spring Harbor Prspectives in Medicine. 2:a006379.
  • Rossler, M., R. Zarski, J. Bohl, and T.G. Ohm. 2002. Stage-dependent and sector-specific neuronal loss in hippocampus during Alzheimer's disease. Acta Neuropathologica. 103:363-369.
  • Rammes, G., R. Rupprecht, U. Ferrari, W. Zieglgansberger, and C.G. Parsons. 2001. The N-methyl-D-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl-cyclohexanes antagonise 5-HT3 receptor currents in cultured HEK-293 and N1E-115 cell systems in a non-competitive manner. Neuroscience Letters. 306:81-84.
  • Rabiei, Z., M. Rafieian-Kopaei, E. Heidarian, E. Saghaei, and S. Mokhtari. 2014. Effects of Zizyphus jujuba extract on memory and learning impairment induced by bilateral electric lesions of the nucleus basalis of meynert in rat. Neurochemical Research. 39:353-360.
  • Prvulovic, D. and B. Schneider. 2014. Pharmacokinetic and pharmacodynamic evaluation of donepezil for the treatment of Alzheimer's disease. Expert Opinion on Drug Metabolism & Toxicology. 10:1039-1050.
  • Poo, M.M. 2001. Neurotrophins as synaptic modulators. Nature Reviews Neuroscience. 2:24-32.
  • Peng, W.H., M.T. Hsieh, Y.S. Lee, Y.C. Lin, and J. Liao. 2000. Anxiolytic effect of seed of Ziziphus jujuba in mouse models of anxiety. Journal of Ethnopharmacology. 72:435-441.
  • Peng, S., J. Wuu, E.J. Mufson, and M. Fahnestock. 2005. Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the pre-clinical stages of Alzheimer's disease. Journal of Neurochemistry. 93:1412-1421.
  • Patapoutian, A. and L.F. Reichardt. 2001. Trk receptors: Mediators of neurotrophin action. Current Opinion in Neurobiology. 11:272-280.
  • Pang, P.T., H.K. Teng, E. Zaitsev, N.T. Woo, K. Sakata, S. Zhen, K.K. Teng, W.H. Yung, B.L. Hempstead, and B. Lu. 2004. Cleavage of proBDNF by tPA/plasmin is essential for long-term hippocampal plasticity. Science. 306:487-491.
  • Olin, J.T. and L. Schneider. 2002. Galantamine for Alzheimer's disease. Cochrane Database of Systematic Reviews. 3:CD001747.
  • Oh, S.B., C.J. Byun, J.H. Yun, D.G. Jo, P. Carmeliet, J.Y. Koh, and J.Y. Lee. 2014. Tissue plasminogen activator arrests Alzheimer's disease pathogenesis. Neurobiology of Aging. 35:511-519.
  • Oakley, H., S.L. Cole, S. Logan, E. Maus, P. Shao, J. Craft, A. Guillozet-Bongaarts, M. Ohno, J. Disterhoft, L. Van Eldik, R. Berry, and R. Vassar. 2006. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: Potential factors in amyloid plaque formation. Journal of Neuroscience. 26:10129-10140.
  • O'Bryant, S.E., V.L. Hobson, J.R. Hall, R.C. Barber, S. Zhang, L. Johnson, R. Diaz- Arrastia, and Texas Alzheimer's Research Consortium. 2011. Serum brain-derived neurotrophic factor levels are specifically associated with memory performance among Alzheimer's disease cases. Dementia and Geriatric Cognitive Disorders. 31:31-36.
  • O'Bryant, S.E., V. Hobson, J.R. Hall, S.C. Waring, W. Chan, P. Massman, L. Lacritz, C.M. Cullum, R. Diaz-Arrastia, and Texas Alzheimer's Research Consortium. 2009. Brain-derived neurotrophic factor levels in Alzheimer's disease. Journal of Alzheimer's Disease. 17:337-341.
  • Noetzli, M. and C.B. Eap. 2013. Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease. Clinical Pharmacokinetics. 52:225-241.
  • Nalivaeva, N.N., C. Beckett, N.D. Belyaev, and A.J. Turner. 2012. Are amyloiddegrading enzymes viable therapeutic targets in Alzheimer’s disease? Journal of Neurochemistry. 120:167-185.
  • Nagahara, A.H., D.A. Merrill, G. Coppola, S. Tsukada, B.E. Schroeder, G.M. Shaked, L. Wang, A. Blesch, A. Kim, J.M. Conner, E. Rockenstein, M.V. Chao, E.H. Koo, D. Geschwind, E. Masliah, A.A. Chiba, and M.H. Tuszynski. 2009. Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease. Nature Medicine. 15:331-337.
  • Mufson, E.J., S.E. Counts, M. Fahnestock, and S.D. Ginsberg. 2007. Cholinotrophic molecular substrates of mild cognitive impairment in the elderly. Current Alzheimer Research. 4:340-350.
  • Michalski, B. and M. Fahnestock. 2003. Pro-brain-derived neurotrophic factor is decreased in parietal cortex in Alzheimer's disease. Molecular Brain Research. 111:148-154.
  • Melchor, J.P., R. Pawlak, and S. Strickland. 2003. The tissue plasminogen activatorplasminogen proteolytic cascade accelerates amyloid-beta (Abeta) degradation and inhibits Abeta-induced neurodegeneration. Journal of Neuroscience. 23:8867-8871.
  • McAllister, A.K., L.C. Katz, and D.C. Lo. 1999. Neurotrophins and synaptic plasticity. Annual Review of Neuroscience. 22:295-318.
  • Marsh, J. and P. Alifragis. 2018. Synaptic dysfunction in Alzheimer's disease: The effects of amyloid beta on synaptic vesicle dynamics as a novel target for therapeutic intervention. Neural Regeneration Research. 13:616-623.
  • Ma, Y., H. Han, J.S. Eun, H.C. Kim, J.T. Hong, and K.W. Oh. 2007. Sanjoinine A isolated from Zizyphi Spinosi Semen augments pentobarbital-induced sleeping behaviors through the modification of GABA-ergic systems. Biological and Pharmaceutical Bulletin. 30:1748-1753.
  • Lu, B., G. Nagappan, and Y. Lu. 2014. BDNF and synaptic plasticity, cognitive function, and dysfunction. Handbook Experimental Pharmacology. 220:223-250.
  • Lovestone, S., M. Boada, B. Dubois, M. Hull, J.O. Rinne, H.J. Huppertz, M. Calero, M.V. Andres, B. Gomez-Carrillo, T. Leon, T. del Ser, and A.R.G.O. investigators. 2015. A phase II trial of tideglusib in Alzheimer's disease. Journal of Alzheimer's Disease. 45:75-88.
  • Liu, Z., X. Zhao, B. Liu, A.J. Liu, H. Li, X. Mao, B. Wu, K.S. Bi, and Y. Jia. 2014. Jujuboside A, a neuroprotective agent from semen Ziziphi Spinosae ameliorates behavioral disorders of the dementia mouse model induced by Abeta1-42. European Journal of Pharmacology. 738:206-213.
  • Liu, J., B. Chen, and S. Yao. 2007. Simultaneous analysis and identification of main bioactive constituents in extract of Ziziphus jujuba var. sapinosa (Zizyphi spinosi semen) by high-performance liquid chromatography-photodiode array detectionelectrospray mass spectrometry. Talanta. 71:668-675.
  • Lemere, C.A., M. Maier, L. Jiang, Y. Peng, and T.J. Seabrook. 2006. Amyloid-beta immunotherapy for the prevention and treatment of Alzheimer disease: Lessons from mice, monkeys, and humans. Rejuvenation Research. 9:77-84.
  • Lee, Y., S.J. Jeon, H.E. Lee, I.H. Jung, Y.W. Jo, S. Lee, J.H. Cheong, D.S. Jang, and J.H. Ryu. 2016. Spinosin, a C-glycoside flavonoid, enhances cognitive performance and adult hippocampal neurogenesis in mice. Pharmacology, Biochemistry, and Behavior. 145:9-16.
  • Lee, S., J. Lee, J. Kim, J. Lee, and S. Kang. 2012. Flavonoids from the seeds of Ziziphus jujuba var. spinosa. Korean Journal of Pharmacognosy. 43:127-136.
  • Lee, J.Y., H.S. Kweon, E. Cho, J.Y. Lee, H.R. Byun, D.H. Kim, Y.H. Kim, P.L. Han, and J.Y. Koh. 2007. Upregulation of tPA/plasminogen proteolytic system in the periphery of amyloid deposits in the Tg2576 mouse model of Alzheimer's disease. Neuroscience Letters. 423:82-87.
  • Lee, H.E., S.Y. Lee, J.S. Kim, S.J. Park, J.M. Kim, Y.W. Lee, J.M. Jung, D.H. Kim, B.Y. Shin, D.S. Jang, S.S. Kang, and J.H. Ryu. 2013. Ethanolic extract of the seed of Ziziphus jujuba var. spinosa ameliorates cognitive impairment induced by cholinergic blockade in mice. Biomolecules and Therapeutics. 21:299-306.
  • Lane, C.A., J. Hardy, and J.M. Schott. 2018. Alzheimer's disease. European Journal of Neurology. 25:59-70.
  • Ko, S.Y., H.E. Lee, S.J. Park, S.J. Jeon, B. Kim, Q. Gao, D.S. Jang, and J.H. Ryu. 2015. Spinosin, a C-glucosylflavone, from Ziziphus jujuba var. spinosa ameliorates Abeta1-42 oligomer-induced memory impairment in mice. Biomolecules and Therapeutics. 23:156-164.
  • Kimura, R. and M. Ohno. 2009. Impairments in remote memory stabilization precede hippocampal synaptic and cognitive failures in 5XFAD Alzheimer mouse model. Neurobiology of Disease. 33:229-235.
  • Kim, J.H. 2016. Chemical compounds in the seeds of Ziziphus jujuba var. spinosa. Korean Herbal Medicine Information. 4:13-28.
  • Jung, I.H., H.E. Lee, S.J. Park, Y.J. Ahn, G. Kwon, H. Woo, S.Y. Lee, J.S. Kim, Y.W. Jo, D.S. Jang, S.S. Kang, and J.H. Ryu. 2014. Ameliorating effect of spinosin, a Cglycoside flavonoid, on scopolamine-induced memory impairment in mice. Pharmacology, Biochemistry, and Behavior. 120:88-94.
  • Jo, S.Y., I.H. Jung, J.H. Yi, T.J. Choi, S. Lee, J.W. Jung, J. Yun, Y.C. Lee, J.H. Ryu, and D.H. Kim. 2017. Ethanol extract of the seed of Ziziphus jujuba var. spinosa potentiates hippocampal synaptic transmission through mitogen-activated protein kinase, adenylyl cyclase, and protein kinase a pathways. Journal of Ethnopharmacology. 200:16-21.
  • Jarosz-Griffiths, H.H., E. Noble, J.V. Rushworth, and N.M. Hooper. 2016. Amyloid-beta receptors: The good, the bad, and the prion protein. The Journal of Biological Chemistry. 291:3174-3183.
  • Jacobsen, J.S., T.A. Comery, R.L. Martone, H. Elokdah, D.L. Crandall, A. Oganesian, S. Aschmies, Y. Kirksey, C. Gonzales, J. Xu, H. Zhou, K. Atchison, E. Wagner, M.M. Zaleska, I. Das, R.L. Arias, J. Bard, D. Riddell, S.J. Gardell, M. Abou-Gharbia, A. Robichaud, R. Magolda, G.P. Vlasuk, T. Bjornsson, P.H. Reinhart, and M.N. Pangalos. 2008. Enhanced clearance of Abeta in brain by sustaining the plasmin proteolysis cascade. Proceedings of The National Academy of Sciences. 105:8754- 8759.
  • Isik, A.T., E. Bozoglu, M.I. Naharci, and S. Kilic. 2010. Evaluation of the effects of galantamine on cardiac function in elderly patients with Alzheimer's disease. The American Journal of Geriatric Pharmacotherapy. 8:454-459.
  • Inglis, F. 2002. The tolerability and safety of cholinesterase inhibitors in the treatment of dementia. International Journal of Clinical Practice. 127:45-63.
  • Ibanez, C.F. 2002. Jekyll-Hyde neurotrophins: The story of proNGF. Trends in Neurosciences. 25:284-286.
  • Hwang, K.H., Y.N. Han, and B.H. Han. 2001. Inhibition of calmodulin-dependent calcium-ATPase and phosphodiesterase by various cyclopeptides and peptide alkaloids from the Zizyphus species. Archives of Pharmacal Research. 24:202- 206.
  • Hung, S.Y. and W.M. Fu. 2017. Drug candidates in clinical trials for Alzheimer's disease. Journal of Biomedical Science. 24:47.
  • Hu, J.P., J.W. Xie, C.Y. Wang, T. Wang, X. Wang, S.L. Wang, W.P. Teng, and Z.Y. Wang. 2011. Valproate reduces tau phosphorylation via cyclin-dependent kinase 5 and glycogen synthase kinase 3 signaling pathways. Brain Research Bulletin. 85:194- 200.
  • Honig, L.S., B. Vellas, M. Woodward, M. Boada, R. Bullock, M. Borrie, K. Hager, N. Andreasen, E. Scarpini, H. Liu-Seifert, M. Case, R.A. Dean, A. Hake, K. Sundell, V. Poole Hoffmann, C. Carlson, R. Khanna, M. Mintun, R. DeMattos, K.J. Selzler, and E. Siemers. 2018. Trial of solanezumab for mild dementia due to Alzheimer's disease. The New England Journal of Medicine. 378:321-330.
  • Hong, M., D.C. Chen, P.S. Klein, and V.M. Lee. 1997. Lithium reduces tau phosphorylation by inhibition of glycogen synthase kinase-3. The Journal of Biological Chemistry. 272:25326-25332.
  • Han, Y.N., G.Y. Kim, K.H. Hwang, and B.H. Han. 1993. Binding of sanjoinine-A (frangufoline) to calmodulin. Archives of Pharmacal Research. 16:289-294.
  • Han, B.H. and M.H. Park. 1987. Alkaloids are the sedative principles of the seeds of Zizyphus vulgaris var. spinosus. Archives of Pharmacal Research. 10:203.
  • Hahn, S.-J. and N.-J. Paik. 2015. Pharmacological treatment of dementia. Brain and Neurorehabilitation. 8:19-23.
  • Gomez-Pinilla, F., S. Vaynman, and Z. Ying. 2008. Brain-derived neurotrophic factor functions as a metabotrophin to mediate the effects of exercise on cognition. The European Journal of Neuroscience. 28:2278-2287.
  • Ghosh, A., J. Carnahan, and M.E. Greenberg. 1994. Requirement for BDNF in activitydependent survival of cortical neurons. Science. 263:1618-1623.
  • Fabbro, S. and N.W. Seeds. 2009. Plasminogen activator activity is inhibited while neuroserpin is up-regulated in the Alzheimer disease brain. Journal of Neurochemistry. 109:303-315.
  • ElAli, A., M. Bordeleau, P. Th riault, M. Filali, A. Lampron, and S. Rivest. 2016. Tissueplasminogen activator attenuates Alzheimer's disease-related pathology development in APPswe/PS1 mice. Neuropsychopharmacology. 41:1297-1307.
  • Drachman, D.A. 2014. The amyloid hypothesis, time to move on: Amyloid is the downstream result, not cause, of Alzheimer's disease. The Journal of The Alzheimer's Association. 10:372-380.
  • Dotti, C.G., C. Galvan, and M.D. Ledesma. 2004. Plasmin deficiency in Alzheimer's disease brains: Causal or casual? Neurodegenerative Diseases. 1:205-212.
  • Devi, L. and M. Ohno. 2012. 7,8-dihydroxyflavone, a small-molecule TrkB agonist, reverses memory deficits and BACE1 elevation in a mouse model of Alzheimer's disease. Neuropsychopharmacology. 37:434-444.
  • Cummings, J., G. Lee, A. Ritter, and K. Zhong. 2018. Alzheimer's disease drug development pipeline: 2018. Alzheimer's and Dementia. 4:195-214.
  • Cumming, J.N., U. Iserloh, and M.E. Kennedy. 2004. Design and development of BACE- 1 inhibitors. Current Opinion in Drug Discovery and Development. 7:536-556.
  • Cordell, G.A., M.L. Quinn‐Beattie, and N.R. Farnsworth. 2001. The potential of alkaloids in drug discovery. Phytotherapy Research. 15:183-205.
  • Chow, V.W., M.P. Mattson, P.C. Wong, and M. Gleichmann. 2010. An overview of APP processing enzymes and products. Neuro Molecular Medicine. 12:1-12.
  • Chen, C.Y., Y.F. Chen, and H.Y. Tsai. 2008. What is the effective component in suanzaoren decoction for curing insomnia? Discovery by virtual screening and molecular dynamic simulation. Journal of Biomolecular Structure and Dynamics. 26:57-64.
  • Chao, M.V. and M. Bothwell. 2002. Neurotrophins: To cleave or not to cleave. Neuron. 33:9-12.
  • Castellino, F.J. and V.A. Ploplis. 2005. Structure and function of the plasminogen/plasmin system. Journal of Thrombosis and Haemostasis. 93:647-654.
  • Cao, J.X., Q.Y. Zhang, S.Y. Cui, X.Y. Cui, J. Zhang, Y.H. Zhang, Y.J. Bai, and Y.Y. Zhao. 2010. Hypnotic effect of jujubosides from Semen Ziziphi Spinosae. Journal of Ethnopharmacology. 130:163-166.
  • Burns, A. and S. Iliffe. 2009. Alzheimer's disease. British Medical Journal. 338:b158. Camps, P. and D. Munoz-Torrero. 2002. Cholinergic drugs in pharmacotherapy of Alzheimer's disease. Mini-Reviews in Medicinal Chemistry. 2:11-25.
  • Birks, J.S. and R.J. Harvey. 2018. Donepezil for dementia due to Alzheimer's disease. Cochrane Database of Systematic Reviews. 18:CD001190.
  • Birks, J.S. and D. Craig. 2006. Galantamine for vascular cognitive impairment. Cochrane Database of Systematic Reviews. 25:CD004746.
  • Bi Oh, S., N. Suh, I. Kim, and J.Y. Lee. 2015. Impacts of aging and amyloid-beta deposition on plasminogen activators and plasminogen activator inhibitor-1 in the Tg2576 mouse model of Alzheimer's disease. Brain Research. 1597:159-167.
  • Barker, R., S. Love, and P.G. Kehoe. 2010. Plasminogen and plasmin in Alzheimer's disease. Brain Research. 1355:7-15.
  • Baranger, K., P. Giannoni, S.D. Girard, S. Girot, F. Gaven, D. Stephan, M. Migliorati, M. Khrestchatisky, J. Bockaert, E. Marchetti-Gauthier, S. Rivera, S. Claeysen, and F.S. Roman. 2017. Chronic treatments with a 5-HT4 receptor agonist decrease amyloid pathology in the entorhinal cortex and learning and memory deficits in the 5XFAD mouse model of Alzheimer's disease. Neuropharmacology. 126:128- 141.
  • Baranello, R.J., K.L. Bharani, V. Padmaraju, N. Chopra, D.K. Lahiri, N.H. Greig, M.A. Pappolla, and K. Sambamurti. 2015. Amyloid-beta protein clearance and degradation (ABCD) pathways and their role in Alzheimer's disease. Current Alzheimer Research. 12:32-46.
  • Autry, A.E. and L.M. Monteggia. 2012. Brain-derived neurotrophic factor and neuropsychiatric disorders. Pharmacological Reviews. 64:238-258.
  • Atif, F., S. Yousuf, I. Sayeed, T. Ishrat, F. Hua, and D.G. Stein. 2013. Combination treatment with progesterone and vitamin D hormone is more effective than monotherapy in ischemic stroke: The role of BDNF/TrkB/Erk1/2 signaling in neuroprotection. Neuropharmacology. 67:78-87.
  • Arbor, S.C., M. LaFontaine, and M. Cumbay. 2016. Amyloid-beta Alzheimer targetsprotein processing, lipid rafts, and amyloid-beta pores. Yale Journal Biology and Medicine. 89:5-21.
  • Arancibia, S., M. Silhol, F. Mouli re, J. Meffre, I. H llinger, T. Maurice, and L. Tapia- Arancibia. 2008. Protective effect of BDNF against beta-amyloid induced neurotoxicity in vitro and in vivo in rats. Neurobiology Disease. 31:316-326.
  • Aracava, Y., E.F. Pereira, A. Maelicke, and E.X. Albuquerque. 2005. Memantine blocks alpha7* nicotinic acetylcholine receptors more potently than n-methyl-Daspartate receptors in rat hippocampal neurons. The Journal of Pharmacology and Experimental Therapeutics. 312:1195-1205.
  • Angelucci, F., K. Čechov , R. Průša, and J. Hort. 2019. Amyloid beta soluble forms and plasminogen activation system in Alzheimer's disease: Consequences on extracellular maturation of brain-derived neurotrophic factor and therapeutic implications. CNS Neurosci and Therapeutics. 25:303-313.